Limited field noncontrast computerized tomography for followup of ureteral stones: initial results.

PURPOSE: Due to high specificity and sensitivity noncontrast computerized tomography is increasingly used to diagnose and follow patients with ureteral stones. We evaluated the feasibility of limited field noncontrast computerized tomography to follow patients with ureteral stones. MATERIALS AND METHODS: Included in the study were 71 patients who underwent diagnostic and followup noncontrast computerized tomography due to ureteral stones. According to stone position on the first diagnostic scan a limited field batch from the followup scan was formed and examined by an independent radiologist. Radiation doses and rates of potentially missed findings in the batch were compared to those of the full followup noncontrast scan. RESULTS: Average full followup noncontrast computerized tomography length was 46.5 cm and average batch length was 20.7 and 13.8 cm for proximal and distal stones, respectively. The average full followup noncontrast scan radiation dose was 12.2 mSv. Average batch doses were 6.1 and 4.1 mSv for proximal and distal stones, respectively (p = 0.002), resulting in a radiation exposure reduction of 48.8% for proximal stones and 66% for distal stones. In 3 cases additional clinical information (not including hydronephrosis) was missed when relying only on batch images. This additional information did not impact further urological treatment. CONCLUSIONS: Limited field noncontrast computerized tomography is a feasible option for following patients diagnosed with ureteral stones. It may lead to significantly lower radiation exposure.

Hospitalizations of patients treated with anti-tumor necrosis factor-α agents -- a retrospective cohort analysis.

OBJECTIVE: To assess the association between treatment with anti-tumor necrosis factor-α (TNF-α) agents and the occurrence of hospitalizations, their causes and complications, compared to treatment with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). METHODS: A retrospective cohort study was conducted of patients with RA, AS, and PsA treated with anti-TNF-α agents between April 2002 and December 2007. Patients were assessed during the period of anti-TNF-α treatment (Group B) and compared to an equivalent period before initiation of anti-TNF-α therapy (Group A). All hospitalization charts were reviewed and diagnoses, comorbidities, concomitant medications, and clinical course were analyzed. Statistical analysis was performed using multivariate mixed Poisson regression. RESULTS: In the study period of 57 months, 735 hospitalization events of 327 patients were analyzed. Statistically significant decreases were seen in the total number of hospitalization events as well as hospitalizations due to exacerbation of rheumatic diseases in Group B compared to Group A (44.4 vs 74.2 and 21.9 vs 47.5 per 100 patient-years, respectively; p < 0.0001). More infectious events (7.4 in Group B compared to 4.6 per 100 patient-years in Group A; p = 0.043) were associated with anti-TNF-α treatment, older age, and underlying disease, because patients with RA had higher rates of infections compared to patients with PsA and patients with AS. CONCLUSION: The overall effect of anti-TNF-α therapy was a significant decline in total hospitalization events. The decrease was more prominent in patients with RA than in patients with AS and patients with PsA, and reflected the significant decrease in hospitalizations due to rheumatic disease exacerbation. The decrease was more pronounced than the observed increase in infectious events.